Phase 3 Trial of FNP122, Oral Form of Edaravone, Starts Enrolling in Europe

Phase 3 Trial of FNP122, Oral Form of Edaravone, Starts Enrolling in Europe

311988

Phase 3 Trial of FNP122, Oral Form of Edaravone, Starts Enrolling in Europe

A first patient has been enrolled in a Phase 3 clinical trial investigating FNP122, an oral formulation of edaravone being developed by Ferrer to treat amyotrophic lateral sclerosis (ALS). The ADORE trial aims to enroll 300 patients across Europe to assess the safety and efficacy of FNP122, as well as its effects on survival. It is being conducted in collaboration with the Treatment Research Initiative to Cure ALS (TRICALS), the largest European research initiative working toward better treatments…

You must be logged in to read/download the full post.